Sana Biotechnology (SANA) Debt Ratio (2021 - 2026)

Sana Biotechnology (SANA) posted Debt Ratio of 0.14 for Q1 2026, up 48.66% sequentially from 0.1 in Q4 2025.

Sana Biotechnology (SANA) Debt Ratio (2021 - 2026) Analysis & Trends

Sana Biotechnology has reported Debt Ratio for 5 years, with the latest figure at 0.14 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.14 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.14 (changed N/A YoY) and the FY2025 annual result came in at 0.1, changed N/A from the prior year.
Debt Ratio rose to 0.14 in Q1 2026 per SANA's latest filing, from 0.1 in the prior quarter.
Over five years, Debt Ratio peaked at 0.14 in Q1 2026 and troughed at 0.05 in Q1 2022.
A 4-year average of 0.08 and a median of 0.07 in 2023 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 87.7% in 2022, down 47.87% in 2022.
Over 4 years, Debt Ratio stood at 0.07 in 2022, then grew by 22.8% to 0.08 in 2023, then advanced by 16.73% to 0.1 in 2025, then surged by 48.66% to 0.14 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.14, 0.1, and 0.08 for Q1 2026, Q4 2025, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Sana Biotechnology	1.06 Bn	1.06 Bn	-	0.21

Download Data